Menu

Question 941

Topic: Biology, Genetics & Bone Healing

Which of the following growth factors is highly osteoinductive, signals via cell-surface serine/threonine kinase receptors to activate the SMAD intracellular pathway, and is FDA-approved for use in open tibia fractures?

. Platelet-derived growth factor (PDGF)
. Vascular endothelial growth factor (VEGF)
. Fibroblast growth factor (FGF)
. Bone morphogenetic protein-2 (BMP-2)
. Transforming growth factor-beta (TGF-b)

Correct Answer & Explanation

. Bone morphogenetic protein-2 (BMP-2)


Explanation

Bone morphogenetic proteins (specifically BMP-2 and BMP-7) are potent osteoinductive growth factors belonging to the TGF-beta superfamily. They bind to serine/threonine kinase receptors and signal intracellularly via the SMAD pathway. rhBMP-2 is FDA approved for use in open tibia fractures and anterior lumbar interbody fusions (ALIF).

Question 942

Topic: Biology, Genetics & Bone Healing

A 30-year-old female presents with a lytic, expansile lesion in the distal femur extending to the subchondral bone. A core needle biopsy confirms a Giant Cell Tumor of bone. If medical therapy is considered, it would typically involve Denosumab. What is the precise mechanism of action of this drug?

. Monoclonal antibody that binds to and inhibits RANK ligand (RANKL)
. Nitrogenous bisphosphonate that inhibits farnesyl pyrophosphate synthase
. Tyrosine kinase inhibitor targeting VEGF receptors
. Monoclonal antibody against CD20 on B-lymphocytes
. Recombinant antagonist of the parathyroid hormone (PTH) receptor

Correct Answer & Explanation

. Monoclonal antibody that binds to and inhibits RANK ligand (RANKL)


Explanation

Denosumab is a fully human monoclonal antibody that binds directly to RANK Ligand (RANKL), preventing it from activating RANK on the surface of osteoclasts and their precursors. In Giant Cell Tumor of bone, the neoplastic stromal cells express high levels of RANKL, which recruits the giant cell osteoclasts that cause bone destruction. Denosumab effectively halts this osteoclastic bone resorption.

Question 943

Topic: Biology, Genetics & Bone Healing

Recombinant human bone morphogenetic protein-2 (rhBMP-2) signals primarily through serine/threonine kinase receptors. Which of the following intracellular signaling molecules is directly phosphorylated following rhBMP-2 receptor activation to initiate osteoblastic gene transcription?

. beta-catenin
. Smad 1/5/8
. JAK/STAT
. c-AMP
. NF-kappa B

Correct Answer & Explanation

. Smad 1/5/8


Explanation

Bone morphogenetic proteins (BMPs) belong to the TGF-beta superfamily. When rhBMP-2 binds to its dimeric serine/threonine kinase receptor, it triggers the intracellular phosphorylation of receptor-regulated Smads, specifically Smad 1, 5, and 8. These complex with Smad 4, translocate to the nucleus, and regulate the transcription of osteogenic genes like Runx2.

Question 944

Topic: Biology, Genetics & Bone Healing

Denosumab is often utilized in the medical management of surgically unsalvageable or recurrent Giant Cell Tumors of Bone (GCTB). What is the specific mechanism of action of this medication?

. Inhibition of the mTOR pathway
. Direct apoptosis of neoplastic mononuclear stromal cells
. Binding and inhibition of the RANK Ligand (RANKL)
. Inhibition of vascular endothelial growth factor (VEGF)
. Cross-linking of DNA preventing tumor cell replication

Correct Answer & Explanation

. Binding and inhibition of the RANK Ligand (RANKL)


Explanation

Giant Cell Tumor of Bone (GCTB) contains neoplastic mononuclear stromal cells that express high levels of RANK Ligand (RANKL). RANKL normally binds to RANK on osteoclast precursors, leading to massive osteoclast-like giant cell formation and bone destruction. Denosumab is a monoclonal antibody that binds to RANKL, preventing it from activating RANK, thereby potently inhibiting osteoclast-mediated bone resorption and stabilizing the tumor.

Question 945

Topic: Biology, Genetics & Bone Healing

Bone morphogenetic proteins (BMPs) play a crucial role in osteoinduction during fracture healing. Following the binding of BMPs to their serine/threonine kinase cell surface receptors, which family of intracellular signaling molecules is directly phosphorylated to translocate to the nucleus and regulate gene transcription?

. JAK/STAT
. MAPK
. Smad
. Wnt/beta-catenin
. Notch

Correct Answer & Explanation

. Smad


Explanation

BMPs signal primarily through the canonical Smad pathway. Binding of BMP to its heterodimeric serine/threonine kinase receptor complex leads to the phosphorylation of receptor-regulated Smads (R-Smads, such as Smad1, 5, and 8), which then complex with the common-partner Smad (Smad4) and translocate to the nucleus to regulate transcription of osteogenic genes.

Question 946

Topic: Biology, Genetics & Bone Healing

A 32-year-old female presents with a large, lytic, eccentrically located epiphyseal lesion in her distal femur. Biopsy reveals multinucleated giant cells in a background of mononuclear stromal cells. She is prescribed denosumab prior to surgical intervention to downstage the tumor. What is the precise mechanism of action of denosumab in treating this tumor?

. It binds directly to the multinucleated giant cells, inducing apoptosis
. It acts as a decoy receptor for RANKL, similar to osteoprotegerin
. It is a monoclonal antibody that binds to RANKL on mononuclear stromal cells, preventing RANK receptor activation on osteoclast precursors
. It inhibits the mammalian target of rapamycin (mTOR) pathway, halting cellular proliferation
. It covalently binds to the IDH1 enzyme, restoring normal cellular metabolism

Correct Answer & Explanation

. It is a monoclonal antibody that binds to RANKL on mononuclear stromal cells, preventing RANK receptor activation on osteoclast precursors


Explanation

In Giant Cell Tumor (GCT) of bone, neoplastic mononuclear stromal cells overexpress Receptor Activator of Nuclear factor Kappa-B Ligand (RANKL), which recruits and activates the reactive multinucleated giant cells via their RANK receptors. Denosumab is a monoclonal antibody that binds directly to RANKL, preventing its interaction with RANK, thereby inhibiting osteoclast-like giant cell formation and reducing osteolysis.

Question 947

Topic: Biology, Genetics & Bone Healing

A 35-year-old woman is diagnosed with an aggressive giant cell tumor (GCT) of the distal radius. Due to the size and proximity to the joint, she is treated with neoadjuvant denosumab prior to surgical curettage. What is the specific mechanism of action of denosumab in the treatment of GCT of bone?

. It is a bisphosphonate that induces apoptosis of osteoclasts.
. It is a monoclonal antibody that binds to and inhibits RANKL.
. It acts as a decoy receptor for RANK (osteoprotegerin analog).
. It inhibits vascular endothelial growth factor (VEGF) to decrease tumor angiogenesis.
. It is a tyrosine kinase inhibitor blocking the c-kit pathway.

Correct Answer & Explanation

. It is a monoclonal antibody that binds to and inhibits RANKL.


Explanation

Denosumab is a fully human monoclonal antibody that binds directly to RANKL (Receptor Activator of Nuclear factor Kappa-B Ligand). In Giant Cell Tumor of bone, the neoplastic mononuclear stromal cells express high levels of RANKL, which recruits and activates the reactive multinucleated giant cells (osteoclast-like cells) responsible for bone destruction. By inhibiting RANKL, denosumab stops the formation and activity of these destructive giant cells.

Question 948

Topic: Biology, Genetics & Bone Healing

In the pathogenesis of acute Charcot neuroarthropathy, pro-inflammatory cytokines play a critical role in increasing the expression of which of the following, leading to amplified osteoclastogenesis?

. Osteoprotegerin (OPG)
. RANKL (Receptor Activator of Nuclear Factor Kappa-B Ligand)
. Bone Morphogenetic Protein-2 (BMP-2)
. Transforming Growth Factor-Beta (TGF-B)
. Sclerostin

Correct Answer & Explanation

. RANKL (Receptor Activator of Nuclear Factor Kappa-B Ligand)


Explanation

In acute Charcot neuroarthropathy, the inflammatory cascade leads to an over-expression of RANKL relative to OPG. This imbalance drives unchecked osteoclastic bone resorption, resulting in the classic osteopenia and bone fragmentation seen in the acute phase.

Question 949

Topic: Biology, Genetics & Bone Healing

Denosumab is highly effective in the management of unresectable Giant Cell Tumor (GCT) of bone. What is the specific cellular target of this monoclonal antibody?

. Vascular Endothelial Growth Factor (VEGF)
. CD20 surface antigen
. RANK Ligand (RANKL)
. Tyrosine kinase domains
. Tumor Necrosis Factor-alpha (TNF-alpha)

Correct Answer & Explanation

. RANK Ligand (RANKL)


Explanation

Denosumab is a fully human monoclonal antibody that binds to RANKL, preventing it from activating RANK on the surface of osteoclasts and their precursors. In GCT, the neoplastic mononuclear stromal cells express RANKL, which recruits and activates the reactive multinucleated giant cells responsible for aggressive bone resorption.

Question 950

Topic: Biology, Genetics & Bone Healing

Bone morphogenetic proteins (BMPs) play a crucial role in osteoblast differentiation and bone formation. Which of the following best describes the intracellular signaling pathway activated immediately upon BMP-2 binding to its serine/threonine kinase cell surface receptor?

. Activation of the Wnt/beta-catenin pathway
. Phosphorylation of Smad 1/5/8 proteins
. Translocation of NF-kappa B to the nucleus
. Upregulation of the RANK ligand
. Inhibition of the MAP kinase pathway

Correct Answer & Explanation

. Phosphorylation of Smad 1/5/8 proteins


Explanation

BMPs bind to dimeric transmembrane serine/threonine kinase receptors. This binding causes phosphorylation and activation of receptor-regulated Smads (R-Smads), specifically Smad 1, 5, and 8. These then form a complex with the co-Smad (Smad 4), which translocates into the nucleus to regulate the transcription of osteogenic target genes like Runx2.

Question 951

Topic: Biology, Genetics & Bone Healing

A 35-year-old female presents with a large, destructive lytic lesion in her distal radius with cortical breakthrough. Biopsy confirms a Giant Cell Tumor (GCT) of bone. Neoadjuvant therapy with denosumab is considered to downstage the tumor prior to curettage. What is the specific mechanism of action of denosumab in treating this lesion?

. It binds to and inhibits RANK, preventing its interaction with RANKL
. It is a monoclonal antibody that binds directly to RANKL, preventing osteoclast activation
. It induces apoptosis of the neoplastic mononuclear stromal cells via the p53 pathway
. It inhibits the MAP kinase pathway directly within the multinucleated giant cells
. It acts as a bisphosphonate, incorporating into bone matrix and poisoning osteoclasts

Correct Answer & Explanation

. It is a monoclonal antibody that binds directly to RANKL, preventing osteoclast activation


Explanation

Denosumab is a fully human monoclonal antibody that binds directly to the Receptor Activator of Nuclear factor Kappa-B Ligand (RANKL). In Giant Cell Tumor of bone, the neoplastic mononuclear stromal cells overexpress RANKL, which recruits and activates the reactive multinucleated giant cells (osteoclast-like cells) responsible for bone destruction. Denosumab inhibits this interaction.

Question 952

Topic: Biology, Genetics & Bone Healing

A 25-year-old woman is diagnosed with a giant cell tumor (GCT) of the distal femur. Her surgeon considers neoadjuvant treatment with Denosumab prior to curettage to facilitate intralesional resection. What is the exact mechanism of action of Denosumab?

. Monoclonal antibody against RANK receptor
. Monoclonal antibody against RANKL
. Direct inhibition of osteoblast activity
. Bisphosphonate analog that induces osteoclast apoptosis
. Tyrosine kinase inhibitor

Correct Answer & Explanation

. Monoclonal antibody against RANKL


Explanation

Denosumab is a fully human monoclonal antibody that binds directly to the Receptor Activator of Nuclear factor Kappa-B Ligand (RANKL), preventing it from binding to the RANK receptor on osteoclasts and their precursors. This effectively inhibits osteoclast-mediated bone destruction, which is the primary driver of osteolysis in Giant Cell Tumor of bone.

Question 953

Topic: Biology, Genetics & Bone Healing

Demineralized bone matrix (DBM) is commonly used in orthopedic procedures as a bone graft extender. Processing allograft bone into DBM preserves which primary biologic property for bone healing?

. Osteogenesis
. Osteoconduction only
. Osteoinduction
. Both osteogenesis and osteoinduction
. Primary structural support

Correct Answer & Explanation

. Osteoinduction


Explanation

Demineralized bone matrix (DBM) undergoes acid extraction of the mineralized phase, which exposes bone morphogenetic proteins (BMPs) and other growth factors. This confers osteoinductive properties to the graft. Because it lacks live cells, it is not osteogenic. While it provides minimal osteoconductive scaffold, its primary therapeutic advantage over cancellous chips is osteoinduction.

Question 954

Topic: Biology, Genetics & Bone Healing

Bone Morphogenetic Proteins (BMPs) play a crucial role in osteoinduction and fracture healing. Biologically, BMPs are members of which of the following larger signaling superfamilies?

. Fibroblast Growth Factor (FGF)
. Platelet-Derived Growth Factor (PDGF)
. Transforming Growth Factor-beta (TGF-beta)
. Insulin-like Growth Factor (IGF)
. Vascular Endothelial Growth Factor (VEGF)

Correct Answer & Explanation

. Transforming Growth Factor-beta (TGF-beta)


Explanation

Bone Morphogenetic Proteins (BMPs) are a group of growth factors structurally classified as part of the Transforming Growth Factor-beta (TGF-beta) superfamily. They bind to serine/threonine kinase receptors on the cell surface and mediate downstream signaling via Smad proteins to induce differentiation of mesenchymal stem cells into osteoblasts.

Question 955

Topic: Biology, Genetics & Bone Healing

During the incorporation of a cortical bone allograft, what is the term used to describe the process where osteoclasts resorb the dead bone and osteoblasts simultaneously lay down new bone in the cutting cone?

. Osteoinduction
. Osteogenesis
. Creeping substitution
. Endochondral ossification
. Intramembranous ossification

Correct Answer & Explanation

. Creeping substitution


Explanation

Creeping substitution is the process by which cortical bone grafts are incorporated. It involves a cutting cone of osteoclasts resorbing the necrotic host bone, closely followed by osteoblasts depositing new viable bone along the pathways.

Question 956

Topic: Biology, Genetics & Bone Healing

Vitamin D plays a critical role in bone metabolism. Following synthesis in the skin or absorption from the gut, it undergoes two sequential hydroxylations to become biologically active. Which specific enzyme is responsible for the final conversion to 1,25-dihydroxyvitamin D (calcitriol)?

. 7-dehydrocholesterol reductase
. 25-hydroxylase in the liver
. 1-alpha-hydroxylase in the kidney
. 24-hydroxylase in the liver
. Tissue non-specific alkaline phosphatase

Correct Answer & Explanation

. 1-alpha-hydroxylase in the kidney


Explanation

Vitamin D is first hydroxylated in the liver by 25-hydroxylase to form 25-hydroxyvitamin D (calcidiol). The final, rate-limiting hydroxylation occurs in the proximal tubules of the kidney, catalyzed by the enzyme 1-alpha-hydroxylase, which converts it to 1,25-dihydroxyvitamin D (calcitriol), its most active form. This step is stimulated by PTH.

Question 957

Topic: Biology, Genetics & Bone Healing

A 68-year-old male presents with a pathologic fracture of the proximal humerus. Radiographs reveal a large 'punched-out' lytic lesion. Laboratory workup shows hypercalcemia, an elevated serum creatinine, and a monoclonal spike on serum protein electrophoresis (SPEP). In the pathophysiology of this disease, what is the primary mechanism driving the extensive osteolysis?

. Increased osteoclast activity driven by tumor cell secretion of RANKL and MIP-1 alpha
. Direct enzymatic osteolytic destruction of bone by invading malignant plasma cells
. Increased osteoblast activity secondary to parathyroid hormone-related peptide (PTHrP) secretion
. Tumor secretion of osteoprotegerin (OPG) leading to uninhibited bone resorption
. Inhibition of vitamin D metabolism by Bence-Jones proteins in the kidney

Correct Answer & Explanation

. Increased osteoclast activity driven by tumor cell secretion of RANKL and MIP-1 alpha


Explanation

The patient has Multiple Myeloma. The characteristic osteolytic bone lesions in multiple myeloma are driven by marked osteoclast activation combined with osteoblast inhibition. Myeloma cells do not destroy bone directly; instead, they secrete various factors, most notably RANKL (Receptor Activator of Nuclear factor Kappa-B Ligand) and MIP-1 alpha (Macrophage Inflammatory Protein-1 alpha), which potently stimulate osteoclast differentiation and activity. They also suppress osteoblast function via DKK-1.

Question 958

Topic: Biology, Genetics & Bone Healing

According to Perren's strain theory, what is the required microstrain environment at the fracture site to promote primary (osteonal) bone healing?

. Less than 2%
. Between 2% and 10%
. Between 10% and 30%
. Greater than 30%
. Strain environment does not dictate primary versus secondary healing

Correct Answer & Explanation

. Less than 2%


Explanation

Perren's strain theory states that primary (osteonal) bone healing occurs under conditions of absolute stability, which corresponds to a local tissue strain of less than 2%. Secondary bone healing (callus formation) occurs in a relatively stable environment with strain between 2% and 10%.

Question 959

Topic: Biology, Genetics & Bone Healing

When selecting a bone graft or substitute for an osseous defect, which of the following materials possesses osteoinductive, osteoconductive, and osteogenic properties?

. Demineralized bone matrix (DBM)
. Cancellous autograft
. Cortical allograft
. Calcium phosphate cement
. Bone morphogenetic protein-2 (BMP-2) on a collagen sponge

Correct Answer & Explanation

. Cancellous autograft


Explanation

Autograft is the only bone graft material that possesses all three essential properties for bone healing: osteoconduction (provides a physical scaffold), osteoinduction (provides growth factors like BMPs to stimulate differentiation), and osteogenesis (supplies live osteoblasts and mesenchymal stem cells).

Question 960

Topic: Biology, Genetics & Bone Healing

Bone morphogenetic proteins (BMPs) play a critical role in osteoinduction and fracture healing. Following the binding of BMP-2 to its transmembrane serine/threonine kinase receptor, which of the following intracellular signaling molecules is phosphorylated to translocate to the nucleus and initiate transcription of osteogenic genes?

. Beta-catenin
. Nuclear factor kappa B (NF-kB)
. SMAD 1/5/8
. Janus kinase (JAK)
. Vascular endothelial growth factor (VEGF)

Correct Answer & Explanation

. SMAD 1/5/8


Explanation

BMP signaling operates primarily through the SMAD pathway. When BMP binds to its serine/threonine kinase receptor, it phosphorylates receptor-regulated SMADs (specifically SMAD 1, 5, and 8). These then form a complex with the co-SMAD (SMAD 4), which translocates to the nucleus to regulate the transcription of target genes necessary for osteoblast differentiation.